PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.11
D/E ratio near Medical - Pharmaceuticals median of 0.12. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
0.33
Exceptionally low net debt at less than half the Medical - Pharmaceuticals median of 1.18. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.
235.08
Coverage of 235.08 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.65
Current ratio below 50% of Medical - Pharmaceuticals median of 2.17. Michael Burry would check for immediate refinancing needs.
0.09%
Intangibles less than half the Medical - Pharmaceuticals median of 3.14%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.